Galectin-8 belongs to a family of mammalian lectins that recognize glycoconjugates present on diff erent cell surface components and modulate a variety of cellular processes. A role of Gal-8 in the immune system has been proposed based on its eff ects in immune cells, including T and B lymphocytes, as well as the presence of anti-Gal-8 autoantibodies in the prototypic autoimmune disease systemic lupus erythematosus (SLE). We have previously described that Gal-8 induces apoptosis in activated T cells interacting with certain β1 integrins and this eff ect is counteracted by the anti-Gal-8 autoantibodies. Given that Gal-8 can potentially interact with several glycoproteins, here we analyzed the β2 integrin Lymphocyte Function-Associated Antigen-1 (LFA-1), which is involved in leukocyte cell adhesion and immunological synapses. We show by GST-pull down assays that Gal-8 interacts with LFA-1 and this interaction is inhibited by anti-Gal-8 autoantibodies isolated from SLE patients. In cell adhesion assays, Gal-8 precluded the interaction of LFA-1 with its ligand Intracellular Adhesion Molecule-1 (ICAM-1). These results suggest that Gal-8 can exert immunosuppressive action not only by inducing apoptosis in activated T cells but also by negatively modulating the crucial function of LFA-1 in the immune system, while function-blocking autoantibodies counteract these eff ects.
INTRODUCTION
Galectins are secreted by an unconventional mechanism and modulate a large variety of cellular processes through cell surface interactions with β-galactosides present in N-and O-glycosylated proteins (Di Lella et al., 2011; Kaltner and Gabius, 2012) . Their presence in the cytosol before secretion also has functional relevance, as they can exert intracellular actions involving protein-protein or lectin-glycan interactions (Bhagatji et al., 2010; Thurston et al., 2012) . Cellular processes that can be modulated by galectin cell surface interactions include cell adhesion, spreading, migration, proliferation, diff erentiation and apoptosis Boscher et al., 2011; Rabinovich et al., 2012) . Galectins also have therapeutic potential by counteracting cellular dysfunctions leading to disease (Rabinovich and Toscano, 2009) .
In accordance with the organization of their carbohydrate recognition domains (CRDs), three different groups of galectins are currently distinguished: 1) Prototype galectins have one CRD and form homodimeric complexes; 2) Tandem repeat galectins have two diff erent CRDs separated by a linker peptide, conforming heterodimer equivalents that can dimerize, leading to tetravalent complexes; 3) A unique chimera type member, Gal-3, has one CRD and a non-lectin domain through which multimers are usually assembled.
Redundant and non-redundant functions of different galectins are accomplished based on the glycan selectivity of their CRDs, subsets of cell surface receptors they recognize and consequential modulation of the corresponding signaling networks (Bi et al., 2008; Lajoie et al., 2009; Boscher et al., 2011; Di Lella et al., 2011; Kaltner and Gabius, 2012) . The CRDs of diff erent galectins and even the N-terminal or C-terminal CRDs of tandem repeat galectins display variations which serve to engage different subsets of functionally distinct glycoproteins (Hirabayashi et al., 2002; Ideo et al., 2003; Patnaik et al., 2006; Stillman et al., 2006; Carlsson et al., 2007; Stowell et al., 2008; Ideo et al., 2011) . Thus, understanding the functions of a particular galectin requires defi ning the range of its interacting elements in diff erent cellular contexts.
Gal-8 is one of the most widely expressed galectins in human tissues (Hadari et al., 1995; Bidon et al., 2001) and is also common in cancerous cells (Bidon-Wagner and Le Pennec 2004; Lahm et al., 2004) . In the immune system Gal-8 can play important roles in the homeostasis of T- Tribulatti et al., 2007; Norambuena et al., 2009; Tribulatti et al., 2009; Tribulatti et al., 2012) and B-cells (Tsai et al., 2011) . Gal-8 expression in the thymus and its pro-apoptotic eff ects on CD4 high CD8 high thymocytes suggest a role in shaping the T cell repertoire (Tribulatti et al., 2007) . Peripheral T cells respond diff erentially to Gal-8 depending on their activation stage. In naïve T cells, Gal-8 at high concentration induces proliferation in the absence of antigen, while at low concentration it costimulates antigen-specifi c activation (Tribulatti et al., 2009 ). Once activated, T cells undergo apoptosis in response to Gal-8, involving an enhanced expression of FasL receptor (Norambuena et al., 2009) . In B cells, Gal-8 promotes diff erentiation toward plasma cells (Tsai et al., 2011) , while neutrophils respond to this lectin by activating their plasma membrane NADPH-oxidase (Nishi et al., 2003) . There is also evidence suggesting an altered Gal-8 function in rheumatic, autoimmune and infl ammatory disorders (Nishi et al., 2003; Eshkar Sebban et al., 2007) . Patients with SLE, the prototypic autoimmune disease, frequently generate anti-Gal-8 autoantibodies that block adhesion and spreading of Jurkat T cells in a Gal-8 matrix . These antibodies also decrease Gal-8-induced apoptosis of Jurkat T cells (Norambuena et al., 2009) . To understand the role of Gal-8 in the immune system and the pathogenic potential of anti-Gal-8 autoantibodies it is necessary to identify functionally relevant Gal-8 counter-receptors.
Gal-8 has been reported to interact with α3β1 and α5β1 integrins , which are both involved in T cell-driven tissue infl ammatory processes (Dustin and de Fougerolles 2001; Pribila et al., 2004) . Anti-Gal-8 autoantibodies produced by lupus patients inhibit these interactions . However, it is very likely that the eff ects of Gal-8 on cells of the immune system do not rely on β1 integrins alone. A previous study suggests that β2 integrin LFA-1 is a putative counter-receptor of Gal-8 (Yamamoto et al., 2008) . LFA-1 is composed of αL and β2 subunits; it plays crucial roles in immune cells (Hogg et al., 2011) and autoimmune diseases such as SLE (Zhang et al., 2013) and is overexpressed in T lymphocytes of patients with SLE (Richardson, 2003) . LFA-1 is a co-stimulatory molecule in immunological synapses between T lymphocytes and APCs (Kuhlman et al., 1991; Hogg et al., 2011) and mediates lymphocyte adhesion to endothelial cells (Hogg et al., 2002) , especially during extravasation in infl amed areas (Sanchez-Madrid and González-Amaro, 2001 ). It also facilitates the adhesion and migration of naïve and memory T cells to secondary lymphoid organs (Rossetti et al., 2002) . ICAM-1 is the major ligand of LFA-1; it is ubiquitously expressed on most leukocytes and endothelial cells, where it is up-regulated during inflammation (Springer, 1990) .
In this study we report that Gal-8 binds to LFA-1 in a carbohydrate-dependent manner, which can be displaced by anti-Gal-8 autoantibodies isolated from SLE patients. We also show that soluble recombinant Gal-8 inhibits the interaction between LFA-1 and its ligand ICAM-1. These results indicate that Gal-8 has the potential to control LFA-1-dependent functions and together with anti-Gal-8 autoantibodies might contribute to modulate immune responses in normal and pathological conditions.
MATERIALS AND METHODS

Expression of recombinant Gal-8
Gal-8 with a glutathione S-transferase (GST) tag was prepared as described previously . Expression of recombinant GST-Gal-8 was induced with 0.2 mM isopropyl-1-thio-β-d-galactopyranoside (Invitrogen, Carlsbad, CA, USA) for 4 h. GST-Gal-8 Glutathione-Sepharose affi nity columns were prepared as described by the manufacturer (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom).
Cell adhesion assays
Gal-8 released from GST by proteolytic treatment was used in cell adhesion assays . 96-well tissue culture plates were coated overnight at 4 °C with 10 μg/ ml of Gal-8 or ICAM-1 in PBS and then were blocked by denatured bovine serum albumin (BSA). Serum-starved PBMC (200000 cells/well), pre-incubated in medium free of FBS for 2 h, were suspended in 1 ml of RPMI and plated in wells for the indicated time periods at 37 °C. Adherent cells were washed twice with PBS, stained and fi xed with 0.2% crystal violet (Sigma) and 10% methanol in H 2 O for 5 min at room temperature. After removing excess dye by washing with H 2 0 and PBS, the cells were solubilized in 0.1 M NaH 2 PO 4 and 50% ethanol for 10 min at room temperature and the absorbance at 570 nanometers was determined. Specific binding was estimated from the diff erence between cells bound to ligandcoated versus denaturated bovine serum albumin-coated wells. All assays were performed in quadruplicate (mean ± SD). Statistics were evaluated using Student's t-test.
GST-Gal-8 pull-down assay
We used a previously described pull-down assay to analyze proteins that interact with Gal-8 (Cárcamo et al., 2006) . PBMC were lysed with 1% NP-40 buff er containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 4 μg/ml leupeptin, 4 mM PMSF, 4 μg/ml antipain and 4 μg/ml pepstatin A (Sigma) for 1 h at 4 °C. Cell lysates were centrifuged at 14,000 rpm for 10 min at 4 °C and supernatants were preincubated with a GST-Sepharose column and then incubated with GST-Sepharose-Gal-8 in the presence or absence of thiodigalactoside (TDG) (10 mM) or anti-Gal-8 antibodies isolated from SLE patients (30 or 60 μg/ml) for 1 h at 4 °C. Beads were then washed with PBS, suspended and boiled in loading buff er. Bound αL integrins were resolved by 10% SDS-PAGE, immunoblotted onto nitrocellulose membranes and visualized by ECL. The results are expressed as mean ± SD.
Isolation of anti-Gal-8 autoantibodies and depleted IgG fraction
Sera from patients with SLE regularly monitored in the Department of Clinical Immunology and Rheumatology, Faculty of Medicine, Catholic University of Chile were obtained with the consent of the donors from the blood bank of the Hospital of the Catholic University of Chile. Sera were screened by immunoblot for autoantibodies against Gal-8 using 0.5 μg of Gal-8 released from GST-Gal-8 as antigen. Sera that gave strong reactivity were used to purify Gal-8 autoantibodies by affi nity chromatography with GST-Gal-8 covalently linked to Affi -Gel 10 (BioRad), according to the manufacturer's instructions. Bound antibodies were eluted with 0.1 M glycine-HCl pH 2.5 solution, neutralized with 1 M K 2 HPO 4 , dialyzed in PBS and maintained in PBS containing 1 mg/ml BSA at −20 °C. The rest of the sera were incubated with protein-A-Sepharose to isolate an IgG fraction depleted from Gal-8 autoantibodies that served as control (C-IgG).
Statistics
All probability values were obtained using Student`s t-test.
RESULTS
To study if Gal-8 binds to LFA-1 we performed pull-down assays and immunoblot analyses. Extracts of freshly isolated peripheral mononuclear cells (PBMCs) (Fig. 1) were incubated with GSTGal-8 in the presence or absence of TDG as specifi c blocker of galectin-glycan interactions. Gal-8 clearly bound LFA-1 in a glycan-dependent manner, as it was inhibited by TDG.
We have previously shown that Gal-8 used as a matrix induces a strong adhesion of PBMCs .
To compare adhesion of PBMCs to Gal-8 and ICAM-1, PBMCs were seeded on 96-well plates coated with 10 μg/ml of either Gal-8 or ICAM-1 and incubated at 37 ºC for diff erent periods of time ( Fig. 2A) . After 15 min of incubation, around 40% of the cells attached to Gal-8, while only 15% of the cells attached to ICAM-1. After 1 h, 100% of the cells were adhered to Gal-8 Figure 1 . Gal-8 binds to αL integrin: Affi nity chromatography assays were performed incubating PBMC extracts with GST-Gal-8 linked to glutathione-Sepharose in the absence or presence of 10 mM TDG. Bound proteins were analyzed by SDS-PAGE and immunoblot against the indicated integrin. Gal-8 binds to aL integrin, through beta-galactosides, as shown by TDG inhibition. Coomassie staining of GST-Gal-8 and total cell extract are also shown Figure 2 . Adhesion of PBMCs to immobilized ICAM-1 is displaced by soluble Gal-8: A) PBMCs (50,000 cells/well) were seeded in serum-free medium on 96-well plates pre-coated with Gal-8 or ICAM-1 (10 µg/ml) and incubated at 37 ºC for the indicated time periods. Adhesion was analyzed by Crystal Violet assay. B) PBMCs pre-incubated with or without soluble Gal-8 were seeded for 30 min on coverslips pre-coated with 10 µg/ml of ICAM-1. Cell nuclei were stained with Hoechst. C) Cell adhesion was quantifi ed by counting cell nuclei in three independent experiments. while only 50% adhered to ICAM-1. When the PBMCs were incubated for 30 min with 10 μg/ml of soluble Gal-8 and then seeded in ICAM-1 coated plates, adhesion was 80% inhibited (Fig. 2B and C) . This last result indicates that Gal-8 interferes with the interaction of LFA-1 and ICAM-1. SLE patients produce autoantibodies against Gal-8 with higher frequency than healthy individuals . Interestingly, these autoantibodies block adhesion, spreading and apoptosis of Jurkat T cells induced by Gal-8 (Norambuena et al., 2009) . Therefore, we analyzed whether these anti-Gal-8 autoantibodies also have the capability to interfere with the interaction between Gal-8 and LFA-1. As shown in pull-down experiments, anti-Gal-8 autoantibodies isolated from the sera samples of three diff erent SLE patients decreased the amount of LFA-1 attached to GST-Gal-8. Using 60 μg/ml (data not shown) the inhibition was similar to the inhibition induced by TDG (Fig. 3, lane 3) . In contrast, IgG purifi ed from the same sera after depleting the Gal-8 autoantibodies did not inhibit the interaction of Gal-8 with LFA-1 (Fig. 3, lane 7 and 8) . The GST control did not bind to this integrin (Fig. 3, lane 1) .
DISCUSSION
Here we show that Gal-8 interacts with LFA-1 in a carbohydrate-dependent manner and that Gal-8 blocks binding of LFA-1 to ICAM-1. We also show that anti-Gal-8 autoantibodies generated by SLE patients block the interaction of Gal-8 with LFA-1. Therefore, Gal-8 has the potential to modulate negatively the crucial function of LFA-1 in the immune system and this role of Gal-8 can be counteracted by Gal-8 autoantibodies.
Previous studies aimed to identify putative Gal-8 counterreceptors detected LFA-1 among other proteins bound to this lectin in affi nity chromatography assays (Yamamoto et al., 2008; Tribulatti et al., 2009) . However, these studies did not provide evidence of functional implications for this putative interaction. Tribulatti et al., (2009) studied Gal-8 bound proteins by mass spectrometry analysis in mice splenocytes and found several leukocyte surface glycoproteins, including previously reported integrins (Hadari et al., 2000; Zick et al., 2004; Cárcamo et al., 2006; Yamamoto et al., 2008) and CD45, as candidate counter-receptors. Their functional studies then focused on CD45, leaving LFA-1 unexplored (Tribulatti et al., 2009) . In Jurkat cells, Yamamoto et al., (2008) reported the interaction between Gal-8 and LFA-1. However, blocking anti-β2 antibodies did not interfere with cell adhesion to Gal-8, therefore they concluded that αL is not a major counterreceptor for Gal-8 (Yamamoto et al., 2008) . Instead, their immunoblot and N-terminal amino acid sequence analysis showed α4 integrin as the major target molecule of Gal-8 in Jurkat cell adhesion assays, which was suppressed by both anti-α4 and -β1 integrin antibodies (Yamamoto et al., 2008) . We previously reported that in Jurkat cells α1, α3 and α5 but not α4 integrins are the main Gal-8 interacting proteins among β1 integrins . Here we clearly detected that αL integrin bound to Gal-8 in pull-down experiments and also showed that Gal-8 can block the interaction of LFA-1 with its natural ligand ICAM-1 in cell adhesion. The discrepancies between the results of Yamamoto and ours are likely due to variations in sub-lines of Jurkat cells. However, we also found similar results using PBMCs from healthy people, which contain around 70% T cells, 20% B cells and 5% monocytes, all known to express LFA-1 on the cell surface (Martz, 1987) . Up to now the interaction with LFA-1 has only been described for Gal-8 and not with any other galectin. Therefore, Gal-8 has the potential to modulate LFA-1 interactions with ICAM-1, and thus might modulate a variety of immunological processes that become dysfunctional in autoimmunity.
L FA -1 m e d i a t e s l y m p h o c y t e c e l l a d h e s i o n a n d immunological synapses; its altered function plays an important pathogenic role in autoimmunity, particularly in the context of hypomethylated DNA (Zhang et al., 2013) . Initial studies found that αL integrin expression is increased in T cells of patients with active SLE, in correlation with their hypomethylated genomic DNA (Richardson et al., 1992) . LFA-1 overexpression in normal T cells is induced by inhibition of DNA methylation with 5-azacytidine (5-azaC) (Richardson et al., 1992) . Overexpression of αL integrin in T cells resulting either from DNA methylation inhibition or from transfection with β2 integrin cDNA leads to T cell autoreactivity in vitro (Richardson et al., 1994) . Adoptive transfer of these cells results in lupus-like disease in mice (Yung et al., 1996) . A similar eff ect is achieved with T cells treated with 5-azaC or procainamide, thus mimicking drug induced lupus-like syndromes (Quddus et al., 1993) . Furthermore, specific sequences fl anking the promoter of the gene encoding aL were found hypomethylated in T cells from patients with active lupus and in T cells treated with 5-azaC and procainamide (Lu et al., 2002) . Recently, two miRNAs (miR-21 and miR148a) that promote cell DNA hypomethylation were found highly elevated in CD4 T cells of SLE patients and in a lupus mouse model (MRL/lpr), together with overexpression of methylation-sensitive genes including LFA-1 (Pan et al., 2010) . On the other hand, conditions that decrease LFA-1 function usually diminish autoimmune reactions. For instance, loss of LFA-1 expression in a lupus mouse model (MRL/MPJ-Fas (Ipr) signifi cantly inhibits the development of infl ammatory disease (Kevil et al., 2004) and treatment of NZB/NZW F-1 lupus mice with blocking LFA-1 antibodies inhibits autoantibody production characteristic of lupus (Connolly et al., 1994) . LFA-1-blocking antibodies also inhibit the development of autoimmune diseases such as diabetes (Bertry-Coussot et al., 2002) , experimental autoimmune encephalitis (EAE) (Gordon et al., 1995) and glomerulonephritis (Nishikawa et al., 1993) in different animal models. All these data indicate that incremented LFA-1 function promotes autoimmune disorders, whereas the contrary occurs when LFA-1 function decreases. Therefore, in addition to inducing apoptosis of activated T cells (Norambuena et al., 2009 ), Gal-8 might also exert an immunosuppressive action by blocking LFA-1 function. It has been reported that Gal-8 is endocytosed after binding to the cell surface (Carlsson et al., 2007) , thus Gal-8 may remove LFA-1 from the cell surface and inhibit its interaction with ICAM-1.
SLE patients are known to produce more than a hundred diff erent autoantibodies (Sherer et al., 2004) , but only a few of them have been directly related to pathogenic mechanisms (Matus, et al., 2007; Tsokos, 2011) . We have previously shown that anti-Gal-8 autoantibodies produced by SLE patients block the interaction of Gal-8 with β1 integrins involved in its apoptotic action upon activated T cells (Norambuena et al., 2009) . Autoantibodies against diff erent members of the galectin family such as Gal-1, -2, -3, and -4 been detected in patients with diff erent types of autoimmune diseases and in cancer (Lutomski et al., 1997; Giordanengo et al., 2001; Jensen-Jarolim et al., 2001; Lim et al., 2002; Romero et al., 2006; Montiel et al., 2010) . However, whether autoantibodies against galectins interfere with galectin function in the immune system and whether they play pathogenic roles are poorly studied. Recently decrease in Gal-1 in synovial fl uids in Rheumatoid Arthritis (RA) patients was correlated with a significant increase in Gal-1 autoantibodies, suggesting a physiological eff ect of these autoantibodies limiting the amount of Gal-1 and potentially blocking its biological eff ect in RA patients (XibilleFriedmann et al., 2013) .
Here, we show that these anti-Gal-8 autoantibodies also block the interaction of Gal-8 with LFA-1, thus providing further evidence of a potential pathogenic role for these autoantibodies.
